Medicure Inc. is a biopharmaceutical company focused on developing therapies for cardiovascular conditions in Canada and the U.S. While it boasts a decent gross margin of 43.1%, its negative EBITDA and net margins raise concerns about profitability. Additionally, a current ratio below 1 suggests potential liquidity issues, despite having no debt. The stock's recent decline of 2.27% may reflect investor caution given these financial challenges, highlighting a need for improved operational efficiency and revenue generation to enhance overall financial health.
Loading financial metrics...
Company is burning $482K per quarter with $1.8M in cash. Approximately 3.8 quarters of runway at current burn rate.
Gross profit margin declined from 54.0% to 38.0% year-over-year, suggesting pricing pressure or rising input costs are squeezing profitability.
Company posted a loss of $-7.5M over the last year, representing 23.2% of revenue.
Exceptional revenue growth of 38.3% YoY demonstrates strong market demand and competitive positioning.
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Low debt-to-revenue ratio of 0.0% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)